Results 61 to 70 of about 34,079 (221)

Follow-up after curative resection for gastric cancer. Is it time to tailor it? [PDF]

, 2017
There is still no consensus on the follow-up frequency and regimen after curative resection for gastric cancer. Moreover, controversy exists regarding the utility of follow-up in improving survival, and the recommendations of experts and societies vary ...
Antolino, L, Aurello, P, D'Angelo, F, Giulitti, D, Petrucciani, N, Ramacciato, G.   +5 more
core   +1 more source

Short‐ and Long‐Term Outcomes of Subtotal Gastrectomy for Remnant Gastric Cancer: A Multicenter Study

Annals of Gastroenterological Surgery, EarlyView.
This multicenter study compared subtotal versus completion gastrectomy for remnant gastric cancer. Subtotal gastrectomy was associated with shorter operative time and significantly less postoperative weight loss, with no difference in long‐term survival, suggesting it as a feasible surgical option without compromising oncologic outcomes.
Kensuke Kudou, Mitsuhiko Ota, Kippei Ogaki, Yasue Kimura, Yuta Kasagi, Naomichi Koga, Hirofumi Hasuda, Tetsuro Kawazoe, Eiji Oki, Tomoharu Yoshizumi   +9 more
wiley   +1 more source

Perioperative and Oncological Outcomes of Colorectal Cancer Surgery in Obese Patients: A Multicenter Retrospective Study

Annals of Gastroenterological Surgery, EarlyView.
The prognostic value of the log odds of positive lymph nodes (LODDS) across BMI categories was investigated in patients undergoing colorectal cancer resection. The exploratory evidence demonstrates that LODDS serves as a strong prognostic marker, and its adverse effect may be more pronounced in patients with higher BMI.
Kazuhiro Taguchi, Manabu Shimomura, Wataru Shimizu, Satoshi Ikeda, Masanori Yoshimitsu, Mohei Kouyama, Masahiro Nakahara, Hironori Kobayashi, Masatoshi Kochi, Yosuke Shimizu, Daisuke Sumitani, Shoichiro Mukai, Yuji Takakura, Yasuyo Ishizaki, Shinya Kodama, Masahiko Fujimori, Hiroshi Okuda, Takuya Yano, Tomoaki Bekki, Atsuhiro Watanabe, Saki Sato, Toshiyuki Moriuchi, Shohei Shiozaki, Kazuki Matsubara, Mizuki Yamaguchi, Tomohiro Adachi, Sho Ishikawa, Hideki Ohdan   +27 more
wiley   +1 more source

Primary leiomyosarcoma of the pancreas: report of a case treated by local excision and review of the literature [PDF]

, 2015
First described by Ross in 1951, primary pancreatic leiomyosarcoma is a rare mesenchymal tumour of the pancreas, with nonspecific clinical and radiological features and a poor prognosis, if ...
Blandamura, Stella, Lico, Valbona, Milanetto, ANNA CATERINA, Pasquali, Claudio   +3 more
core   +1 more source

Prognostic Value of Psoas Major Muscle Volume in Assessing Sarcopenia in Elderly Patients With Rectal Cancer

Annals of Gastroenterological Surgery, EarlyView.
This study investigates the prognostic utility of a novel volumetric indicator—psoas volume index (PVI)—for assessing sarcopenia in elderly rectal cancer patients. Sarcopenia classified by our proposed PVI cut‐off values was associated with poor nutritional and inflammatory status, and patients with low PVI showed significantly worse long‐term outcomes.
Gen Tsujio, Shoichi Manabe, Akio Shiomi, Yusuke Tanaka, Shunsuke Kasai, Tadahiro Kojima, Takahiro Igaki, Yukihiro Mori, Akifumi Notsu   +8 more
wiley   +1 more source

Novel diagnostic and prognostic biomarkers in biliary tract cancer. [PDF]

, 2013
The worldwide incidence of biliary tract carcinoma (BTC, tumours of the bile ducts and gall-bladder) continues to rise, with the only potentially curative treatment remaining surgical resection or transplantation, possible in only a minority of patients.
Pereira, SP, Skipworth, JR, Timms, JF
core   +1 more source

Prognostic Significance of Portal Vein Tumor Thrombus in Pancreatic Ductal Adenocarcinoma Treated With Chemoradiotherapy

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim To examine the significance of portal vein tumor thrombus (PVTT) as a prognostic factor for patients with pancreatic ductal adenocarcinoma (PDAC) treated with chemoradiotherapy (CRT) followed by surgery. Methods The study retrospectively examined 313 patients with borderline resectable (BR) or locally advanced (LA) PDAC who underwent CRT ...
Aoi Hayasaki, Motonori Nagata, Miki Usui, Hiroshi Imai, Yusuke Iizawa, Akihiro Tanemura, Yasuhiro Murata, Naohisa Kuriyama, Masashi Kishiwada, Shugo Mizuno   +9 more
wiley   +1 more source

Targeting the insulin growth factor-1 receptor with fluorescent antibodies enables high resolution imaging of human pancreatic cancer in orthotopic mouse models. [PDF]

, 2016
The goal of the present study was to determine whether insulin-like growth factor-1 receptor (IGF-1R) antibodies, conjugated with bright fluorophores, could enable visualization of pancreatic cancer in orthotopic nude mouse models. IGF-1R antibody (clone
Bouvet, Michael, Hoffman, Robert M, Lee, Jin Young, Park, Jeong Youp, Zhang, Yong   +4 more
core   +2 more sources

Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial [PDF]

, 2017
BACKGROUND: The ESPAC-3 trial showed that adjuvant gemcitabine is the standard of care based on similar survival to and less toxicity than adjuvant 5-fluorouracil/folinic acid in patients with resected pancreatic cancer.
Akaike, Alan Anthoney, Alec McDonald, Bengt Glimelius, Campbell, Capello, Christopher M Halloran, Conroy, Cox, Cunningham, Daniel H Palmer, David Borg, David Cunningham, David Sherriff, Derek A O'Reilly, Eftychia E Psarelli, Gary William Middleton, Greenhalf, Harpreet Wasan, Henderson, Jakob R Izbicki, John P Neoptolemos, Jonathan Wadsley, Juan W Valle, Kinnari Patel, Kleeff, Liao, Markus W Büchler, Neoptolemos, Neoptolemos, Neoptolemos, Neoptolemos, Neoptolemos, Oettle, Olusola Faluyi, Pascal Hammel, Paul J Ross, Paula Ghaneh, Pehr Lind, Peto, Peto, Reni, Richard Jackson, Roopinder Gillmore, Rubin Soomal, Schemper, Schoenfeld, Sebastian Cummins, Sharmila Sothi, Sinn, Stephen Falk, Sultana, Suzanne Darby, Thilo Hackert, Tim Meyer, Tom Crosby, Trotti, Uesaka, Valle, Vivaldi, Von Hoff, White, Yuk Ting Ma   +62 more
core   +6 more sources

CA19-9 in Mature Cystic Teratoma.

The Tohoku Journal of Experimental Medicine, 1994
I investigated 250 patients with mature cystic teratoma (MCT) of ovary, using an enzyme immunoassay to determine the tissue source of their high serum levels of CA19-9. The mean preoperative serum CA19-9 level was 79.4 U/ml, and the mean postoperative level was far lower (27.4 U/ml). There were 41 patients positive for CA19-9. In the 31 with serum CA19-
openaire   +3 more sources